Our research group is conducting a broad spectrum of clinical trials.
Ongoing Clinical Studies
The NAFLD Registry Study
Status: Currently recruiting subjects
Required visits: Single visit
Age of participants: Greater than 18 years
Gender of participants: Male and Female
Additional Details
The Adult Database 2 Study
Status: Currently recruiting subjects
Required visits: Single visit
Age of participants: Greater than 18 years
Gender of participants: Male and Female
Additional Details
The Twin and Family Study
Status: Currently recruiting subjects
Required visits: Single visit
Age of participants: Greater than 18 years
Gender of participants: Male and Female
Additional Details
Familial Cirrhosis
Status: Currently recruiting subjects
Required visits: Single visit
Age of participants: Greater than 18 years
Gender of participants: Male and Female
Additional Details
ARRIVE Study
Among patients with HIV infection, liver disease is one of the leading causes of death. Progression of liver disease in HIV is linked to metabolic derangements associated with hepatic steatosis. Currently, there is no FDA approved treatment for HIV-associated NAFLD and this area remains understudied. The purpose of the ARRIVE study is to examine the efficacy of Aramchol , comparing 600 mg daily (including 200 mg tablet and 400 mg tablet) versus identical placebo in improving hepatic steatosis assessed by magnetic resonance imaging in patients with HIV-associated NAFLD.
This study is a randomized, double-blind, placebo-controlled clinical trial to examine the efficacy of aramchol 600 mg daily (including 200 mg tablet and 400 mg tablet) versus identical placebo given over 12 weeks to improve HIV- associated hepatic steatosis as measured by a validated and accurate magnetic resonance imaging (MRI)-based technique.
Patients will be initially screened in the UCSD NAFLD research center clinic with history, physical examination, review of outside medical records (including HIV status) and routine blood tests. Those who meet all eligibility criteria will undergo more thorough evaluation with liver MRI, cardiac MRI, Ultrasound transient elastography with CAP and DEXA scan for total body fat.
The ARRIVE study consists of up to four follow-up visits. The screening visit will take approximately 2 hours with each follow up visit taking approximately 1.5 hours. Study participants will be asked to come in a fasting state for the blood draw and will receive a physical exam and undergo imaging (magnetic resonance techniques and ultrasound). In addition, participants will be asked questions about alcohol consumption and medication use.
Status: Currently recruiting subjects
Required visits: Single visit
Age of participants: Greater than 18 years
Gender of participants: Male and Female
Informed Consent Forms:
General Adult Consent
Genetic Consent
For additional questions regarding this study please contact:
Shirin Bassirian
Clinical Research Coordinator
Phone: (858)-246-2256
Email: sbassirian@ucsd.edu